"I am very honored to be the CEO of the company and would like to thank the founder Professor Xiao, the board of directors and all staffs of HopeMed for their trust and support. I am looking forward to expanding and influencing even further HopeMed's innovative R&D activities and continue to work alongside with the founder Professor Xiao to create more value for the company and help patients still in need for better treatments. Hope Medicine is a unique biotech in China, it has a talented team, dedicated investors, an attractive FiC research portfolio and most importantly a frontrunner asset HMI-115 that has got IND approval from the US FDA for Phase II clinical trial in endometriosis, and patient recruitment for the US Phase II clinical trial will start by Q4 of this year. It is an exciting time for the company, and I am committed to the mission and together with the team will drive innovation out of China to successfully reach our long-term vision to become a biopharmaceutical company serving the needs of patients globally." said by Dr. Doods.